Delay in presentation, an indicator for nerve function status at registration and for treatment outcome - The experience of the Bangladesh Acute Nerve Damage Study cohort

Leprosy Review

Volumn 74, Issue 4, 2003, Pages 349-356

  Nicholls, P G ^a   Croft, R P ^b   Richardus, J H ^c   Withington, S G ^d   Smith, W C S ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b University Medical Center Rotterdam ^*  (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Danish Bangladesh Leprosy Mission   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; BANGLADESH; COHORT ANALYSIS; DISABILITY; FEMALE; HUMAN; LEPROSY; MAJOR CLINICAL STUDY; MALE; NERVE FUNCTION; NERVE FUNCTION IMPAIRMENT; NEUROPATHY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; COHORT STUDIES; COMMUNICABLE DISEASE CONTROL; CONFIDENCE INTERVALS; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; NEPAL; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDNISOLONE; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0348048502     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Anonymous. WHO Expert Committee on Leprosy. World Health Organization Technical Report Series 1998; 874: 1-43.
2. Meima A, Saunderson PR, Gebre S et al. Factors associated with impairments in new leprosy patients: the AMFES cohort. Lepr Rev, 1999; 70: 189-203.
3. Schreuder PA. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study. Int J Lepr Other Mycobact Dis, 1998; 66: 149-158.
4. Wittenhorst B, Vree ML, Ten Ham PB, Velema JP. The National Leprosy Control Programme of Zimbabwe a data analysis, 1983-1992. Lepr Rev, 1998; 69: 46-56.
5. Hastings R. Leprosy. Churchill Livingstone, Edinburgh, 1985.
6. Anonymous. Annual Report 2000-2001. ILEP, 2001.
7. Anonymous. Guide to eliminate leprosy, 2000 edn. WHO, Geneva, 2000.
8. Saunderson P. Report of workshop on organization of leprosy services under low-endemic conditions. Int J Lepr Other Mycobact Dis, 1998; 66: 574-575.
9. Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev, 1999; 70: 140-159.
10. Croft RP, Nicholls PG, Richardus JH, Smith WC. Incidence rates of acute nerve function impairment in leprosy: a prospective cohort analysis after 24 months (The Bangladesh Acute Nerve Damage Study). Lepr Rev, 2000; 71: 18-33.
11. Croft RP, Nicholls PG, Steyerberg EW et al. A clinical prediction rule for nerve-function impairment in leprosy patients. Lancet, 2000; 355: 1603-1606.
12. Croft RP, Nicholls PG, Richardus JH, Smith WC. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev, 2000; 71: 154-168.
13. Croft RP, Smith WC, Nicholls P, Richardus JH. Sensitivity and specificity of methods of classification of leprosy without use of skin smear examination. Int J Lepr Other Mycobact Dis, 1998; 66: 445-450.
14. Heynders ML, Meijs JJ, Anderson AM. Towards an understanding of non-compliance. An assessment of risk factors for defaulting from leprosy treatment. Lepr Rev, 2000; 71: 369-376.
15. Anonymous. Progress towards the elimination of leprosy as a public health problem. Weekly Epidemiol Rec, 1995; 70: 177-182.